Agios plans Q2 sNDA filing for mitapivat in sickle cell disease while citing >$10B 2030 market opportunity

Q1 2026 Management View Brian Goff (CEO & Director) said the company is “off to a strong start entering another catalyst-rich year,” highlighting $20.7 million in net revenues and “138% growth ...
Seeking Alpha

Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript

Good morning, and welcome to the Agios Pharmaceuticals Investor Conference Call and Webcast. [Operator Instructions] Please be advised that this call is being recorded at Agios' request. I would now ...
Seeking Alpha

Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript

Good day, and welcome to Agios Pharmaceuticals' Investor Conference Call and Webcast. [Operator Instructions] Please be advised that this call is being recorded at Agios' request. I would now like to ...
Seeking Alpha

Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript

Good morning, and welcome to Agios Pharmaceuticals Third Quarter 2025 Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Agios' request. I would now like to ...
Seeking Alpha

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Tess Romero, and I'm one of the senior biotech analysts here at JPMorgan. Our next presenting company is Agios, and ...
Seeking Alpha

Agios Pharmaceuticals, Inc. (AGIO) Q4 2025 Earnings Call Transcript

Good morning, and welcome to Agios Pharmaceuticals Fourth Quarter and Full Year 2025 Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Agios' request. I ...